Dihexa
A synthetic peptide fragment claimed to be millions of times more potent than BDNF for synapse formation. Dihexa targets the HGF/c-Met pathway to promote new neural connections — but the evidence is limited and the safety profile is essentially unknown.
Dihexa is a modified angiotensin IV analogue that activates the HGF/c-Met pathway — involved in neurogenesis and synaptogenesis (forming new neurons and connections). In animal studies, it enhanced memory and reversed cognitive impairment. It is extremely potent at low doses but has minimal safety data.
Who's interested: Nootropic enthusiasts and biohackers pursuing cognitive enhancement. This is a high-risk, high-uncertainty compound — not for cautious users.
Dive deeper into the researchPotential side effects
- Unknown — no human safety studies
- Theoretical cancer risk from HGF/c-Met activation (a growth pathway)
- Potential cardiovascular effects from angiotensin system interaction
What does Dihexa do?
Dihexa was developed at Washington State University as a cognitive enhancer. It works by activating the HGF/c-Met pathway — a signaling system involved in forming new synapses (connections between neurons) and promoting neuronal survival.
In rat studies, Dihexa was described as being "seven orders of magnitude more potent" than BDNF for promoting synaptogenesis. Treated animals showed improved spatial memory and reversal of scopolamine-induced cognitive impairment.
Who uses it?
- Nootropic users — those seeking cognitive enhancement beyond typical racetams
- Cognitive decline concerns — people interested in preventive neuroprotection
- Brain injury recovery — some use it experimentally for post-TBI cognitive support
What to know before trying
Dihexa activates HGF/c-Met — a pathway also involved in cancer cell growth and metastasis. While no evidence directly links Dihexa to cancer, this mechanism warrants extreme caution. There are zero human safety studies.
- Extremely potent — active at very low doses (mg range sublingually)
- No human trials — all data from rat studies at Washington State University
- Cancer pathway concern — HGF/c-Met is a known oncogenic pathway
- Quality concerns — few vendors, minimal third-party verification available
Tracking a peptide protocol?
eterni connects your labs, supplements, and retests — so you can see whether your protocol is actually working.
Get early accessFrequently Asked Questions
What is Dihexa and how does it work?
Dihexa is a synthetic hexapeptide analogue of angiotensin IV that activates the HGF/c-Met signaling pathway to promote synaptogenesis (new neural connections) and neuronal survival. In animal studies, it enhanced spatial memory and reversed cognitive impairment.
Is Dihexa safe?
Unknown. No human safety data exists. The primary concern is that Dihexa activates HGF/c-Met — a pathway also involved in cancer cell proliferation and metastasis. While no direct cancer link has been established, this mechanism raises legitimate safety questions.
How does Dihexa compare to other nootropics?
Dihexa works through a completely different mechanism (HGF/c-Met) than racetams (cholinergic), modafinil (dopaminergic), or semax (neurotrophic). It is theoretically more potent for synaptogenesis but carries more uncertainty and risk than established nootropics.
Is Dihexa available in India?
Some research chemical vendors carry Dihexa, but availability is limited. It is not approved for any use in any country. Sourcing and quality verification are significant challenges.
How it works
- HGF/c-Met activation — stimulates hepatocyte growth factor receptor, driving synaptogenesis
- Angiotensin IV analogue — derived from angiotensin IV with modifications for stability and potency
- Synaptogenesis — promotes formation of new dendritic spines and synaptic connections
- Blood-brain barrier — penetrates BBB effectively via sublingual and intranasal routes
Animal evidence
- Reversed scopolamine-induced cognitive impairment in rats
- Enhanced spatial learning in Morris water maze tests
- Promoted spinogenesis and synaptogenesis in hippocampal neurons
- Described as 10^7 more potent than BDNF for synapse formation in vitro
Side effects & safety
Completely unknown in humans. Key theoretical concerns:
- Cancer risk — HGF/c-Met is a known proto-oncogenic pathway; chronic activation could theoretically promote tumor growth
- Cardiovascular effects — angiotensin system involvement could affect blood pressure
- Neurotoxicity — excessive synaptogenesis could theoretically cause seizure susceptibility
- Unknown dose-response — therapeutic window in humans is completely uncharacterised
Who should avoid it: Anyone with a history of cancer, cardiovascular disease, seizure disorders, or who is pregnant/breastfeeding. Arguably, most people should avoid it given the zero human data and cancer-pathway concerns.
Know what's working. Know what's not.
eterni connects your lab results, supplements, and retests — so you can see the trajectory, not just a snapshot.
Join the waitlist